Loading ...Dr Wakefield was talking about the immune response in animals and this vaccine has no studies. That ls why the prior attempt to get a SARS vaccine was stopped because it killed them. Now they don’t need the studies so they’re going ahead.
Here’s one of the articles I would of posted earlier but the site was down.
Vaccine immune response
What Dr Tenpenny was talking about in the immune response.
The antibody to the spike protein is going to destroy your lungs.
The antibody to the spike protein is going to shut off M2 anti inflammatory macrophages that calm down and heal the body after the M1 that brings cytokines but the antibody stops the M2 from shutting off the M1 “ meaning ARDS cytokine storm”!and the antibody to the spike protein is going to loosely bind to the mRNA and drag it inside your cell and cause a Trojan horse phenomenon making it replicate and have this process continue because it’s a on button without a off button.
When you look at all the studies when you go back to 2002 when they tried to developer a corona virus vaccine, you get these antibodies and then garden variety corona virus show up and there’s many, and that’s what activated the whole process. ADE.
A few paragraphs in this article with references below it in the link,
Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity
Failure of SARS and MERS vaccines in animal trials involved pathogenesis consistent with an immunological priming that could involve autoimmunity in lung tissues due to previous exposure to the SARS and MERS spike protein. Exposure pathogenesis to SARS-CoV-2 in COVID-19 likely will lead to similar outcomes. Immunogenic peptides in viruses or bacteria that match human proteins are good candidates for pathogenic priming peptides (similar to the more diffuse idea of “immune enhancement”).
In SARS, a type of “priming” of the immune system was observed during animal studies of SARS spike protein-based vaccines leading to increased morbidity and mortality in vaccinated animals who were subsequently exposed to wild SARS virus. The problem, highlighted in two studies, became obvious following post-vaccination challenge with the SARS virus [2]. found that recombinant SARS spike-protein-based vaccines not only failed to provide protection from SARS-CoV infection, but also that the mice experienced increased immunopathology with eosinophilic infiltrates in their lungs. Similarly [3], found that ferrets previously vaccinated against SARS-CoV also developed a strong inflammatory response in liver tissue (hepatitis). Both studies suspected a “cellular immune response”.
These types of unfortunate outcomes are sometimes referred to as “immune enhancement”; however, this nearly euphemistic phrase fails to convey the increased risk of illness and death due to prior exposure to the SARS spike protein. For this reason, I refer to the concept as “pathogen priming”; the peptides with pathogenic potential therefore are referred to as “putative pathogenic priming peptides”.